Establishment and Characterization of Multi-Drug Resistant p53-Negative Osteosarcoma SaOS-2 Subline
Diagnostics · 11.08.2023 · 13 (16) · 2646
DOI: 10.3390/diagnostics13162646 ↗Kurz gefasst
Fachartikel in der Zeitschrift Diagnostics, online erschienen am 11.08.2023. Verfasst von Sergei Boichuk und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Kazan State Medical University, Kazan 420012, Russia. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Russian Science Foundation.
Abstract (Originalsprache)
Aim
To establish a p53-negative osteosarcoma (OS) SaOS-2 cellular subline exhibiting resistance to specific chemotherapeutic agents, including topoisomerase II inhibitors, taxanes, and vinca alkaloids.
Methods
The OS subline exhibiting resistance to the chemotherapeutic agents indicated above was generated by the stepwise treatment of the parental SaOS-2 cell line with increasing concentrations of doxorubicin (Dox) for 5 months. Half-inhibitory concentrations (IC50) for Dox, vinblastine (Vin), and paclitaxel (PTX) were calculated by a colorimetric MTS-based assay. Crystal violet staining was used to assess cellular viability, whereas the proliferation capacities of cancer cells were monitored in real-time by the i-Celligence system. Expression of apoptotic markers (e.g., cleaved PARP and caspase-3), DNA repair proteins (e.g., ATM, DNA-PK, Nbs1, Rad51, MSH2, etc.), and certain ABC transporters (P-glycoprotein, MRP1, ABCG2, etc.) was assessed by western blotting and real-time PCR. Flow cytometry was used to examine the fluorescence intensity of Dox and ABC-transporter substrates (e.g., Calcein AM and CMFDA) and to assess their excretion to define the activity of specific ABC-transporters. To confirm OS resistance to Dox in vivo, xenograft experiments were performed.
Results
An OS subline generated by a stepwise treatment of the parental SaOS-2 cell line with increasing concentrations of Dox resulted in an increase in the IC50 for Dox, Vin, and PTX (~6-, 4-, and 30-fold, respectively). The acquisition of chemoresistance in vitro was also evidenced by the lack of apoptotic markers (e.g., cleaved PARP and caspase-3) in resistant OS cells treated with the chemotherapeutic agents indicated above. The development of the multidrug resistance (MDR) phenotype in this OS subline was due to the overexpression of ABCB1 (i.e., P-glycoprotein) and ABCC1 (i.e., multidrug resistance protein-1, MRP-1), which was evidenced on both mRNA and protein levels. Due to increased expression of MDR-related proteins, resistant OS exhibited an excessive efflux of Dox. Moreover, decreased accumulation of calcein AM, a well-known fluorescent substrate for both ABCB1 and ABCC1, was observed for resistant OS cells compared to their parental SaOS-2 cell line. Importantly, tariquidar and cyclosporin, well-known ABC inhibitors, retained the intensity of Dox-induced fluorescence in resistant SAOS-2 cells. Furthermore, in addition to the increased efflux of the chemotherapeutic agents from Dox-resistant OS cells, we found higher expression of several DNA repair proteins (e.g., Rad51 recombinase, Mre11, and Nbs1, activated forms of ATM, DNA-PK, Chk1, and Chk2, etc.), contributing to the chemoresistance due to the excessive DNA repair. Lastly, the in vivo study indicated that Dox has no impact on the SaOS-2 Dox-R xenograft tumor growth in a nude mouse model.
Conclusions
An acquired resistance of OS to the chemotherapeutic agents might be due to the several mechanisms undergoing simultaneously on the single-cell level. This reveals the complexity of the mechanisms involved in the secondary resistance of OS to chemotherapies.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pathology, Kazan State Medical University, Kazan 420012, Russia.
- "Biomarker" Research Laboratory, Institute of Fundamental Medicine and Biology, Kazan Federal University, Kazan 420008, Russia.
- Department of Radiotherapy and Radiology, Russian Medical Academy of Continuous Professional Education, Moscow 125993, Russia.
- Central Research Laboratory, Kazan State Medical University, Kazan 420012, Russia.
- Cytogenetics Laboratory, Carcinogenesis Institute, N.N. Blokhin National Medical Research Center of Oncology, Moscow 115478, Russia.
- Department of Biochemistry, Kazan State Medical University, Kazan 420012, Russia.
ORCID-Profile: Sergei Boichuk, Firyuza Bikinieva, Pavel Kopnin, Aigul Galembikova
Förderung
- Russian Science Foundation
Zitieren
APA
Boichuk, S., Bikinieva, F., Valeeva, E., Dunaev, P., Vasileva, M., Kopnin, P., Mikheeva, E., Ivoilova, T., Mustafin, I., & Galembikova, A. (2023). Establishment and Characterization of Multi-Drug Resistant p53-Negative Osteosarcoma SaOS-2 Subline. Diagnostics, 13(16), 2646. https://doi.org/10.3390/diagnostics13162646
Vancouver
Boichuk S, Bikinieva F, Valeeva E, Dunaev P, Vasileva M, Kopnin P, et al. Establishment and Characterization of Multi-Drug Resistant p53-Negative Osteosarcoma SaOS-2 Subline. Diagnostics. 2023;13(16):2646. doi:10.3390/diagnostics13162646
BibTeX
@article{Boichuk2023,
author = {Boichuk, Sergei and Bikinieva, Firyuza and Valeeva, Elena and Dunaev, Pavel and Vasileva, Maria and Kopnin, Pavel and Mikheeva, Ekaterina and Ivoilova, Tatyana and Mustafin, Ilshat and Galembikova, Aigul},
title = {Establishment and Characterization of Multi-Drug Resistant p53-Negative Osteosarcoma SaOS-2 Subline},
journal = {Diagnostics},
year = {2023},
volume = {13},
number = {16},
pages = {2646},
doi = {10.3390/diagnostics13162646}
}
EUVIMED